Login to Your Account



Realm raises $19.3M, emerges with immunotherapy pipeline

By Nuala Moran
Staff Writer

Friday, September 22, 2017

LONDON – Realm Therapeutics plc has sold U.S. and U.K. specialist health care funds on its transformation from disinfection services company to immunotherapy specialist, raising £19.3 million in a placing to advance its hypochlorous acid product through phase IIb in atopic dermatitis and allergic conjunctivitis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription